Irinotecan-induced muscle twitching from a possible drug interaction: A case report (Q40107303)

17 September 2017

title

Irinotecan-induced muscle twitching from a possible drug interaction: A case report (English)

1 reference

17 September 2017

1 reference

S S Peters

1

1 reference

17 September 2017

J Bettinger

2

1 reference

17 September 2017

J Philip

3

1 reference

17 September 2017

B Karhan

4

1 reference

17 September 2017

S H Wrzesinski

5

1 reference

17 September 2017

publication date

1 January 2017

1 reference

Journal of Oncology Pharmacy Practice

17 September 2017

published in

1 reference

17 September 2017

page(s)

1078155217723696

1 reference

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Irinotecan-induced dysarthria: A case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Modulation of irinotecan metabolism by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

Clinical practice guideline: Bell's Palsy executive summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155217723696

21 January 2018

Identifiers

DOI

10.1177/1078155217723696

1 reference

17 September 2017

1 reference